A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring CABG, Anginera, CAD
Eligibility Criteria
Inclusion Criteria: Patients have been referred for CABG Left ventricular ejection fraction (LVEF) greater than 20% Patients have CAD involving at least two (2) coronary arteries, with at least one or more vessel(s) having disease not amenable to bypass grafting or PCI There is a region of myocardium served by the vessel(s) defined above that has objective evidence of multi-distribution reversible ischemia based on a 17-segment assessment of reversible defects on SPECT/Thallium. Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from the study: Patient undergoing valve replacement or valve modification Patient with significant or malignant ventricular arrhythmias, defined as a patient being treated for ventricular tachycardia and/or ventricular fibrillation with an implantable cardioverter/defibrillator (ICD) or a patient being treated with Amiodarone for these same tachyarrhythmias. (Note: having an implantable cardioverter/defibrillator (ICD) per se, in a patient who does not have significant or malignant ventricular arrhythmias, does not exclude the patient from this study.) Patient requires urgent coronary artery bypass surgery
Sites / Locations
- Yale University School of Medicine,
- University of Maryland School of Medicine